Comparing the effects of tofogliflozin and pioglitazone in non-alcoholic fatty liver disease patients with type 2 diabetes mellitus (ToPiND study): a randomized prospective open-label controlled trial

Assessing the Risk for Gout With Sodium–Glucose Cotransporter-2 Inhibitors in Patients With Type 2 Diabetes

(2020) Michael Fralick et al.   ANNALS OF INTERNAL MEDICINE

Multicenter validation of association between decline in MRI‐PDFF and histologic response in nonalcoholic steatohepatitis

(2020) Rohit Loomba et al.   HEPATOLOGY

A diabetologist’s perspective of non‐alcoholic steatohepatitis (NASH): Knowledge gaps and future directions

(2020) Kenneth Cusi   LIVER INTERNATIONAL

SGLT2 inhibitors: mechanisms of cardiovascular benefit beyond glycaemic control

(2020) Martin R. Cowie et al.   Nature Reviews Cardiology

Role of Agents for the Treatment of Diabetes in the Management of Nonalcoholic Fatty Liver Disease

(2020) Jeffrey Budd et al.   Current Diabetes Reports

Role of ketogenic starvation sensors in mediating the renal protective effects of SGLT2 inhibitors in type 2 diabetes

(2020) Milton Packer   JOURNAL OF DIABETES AND ITS COMPLICATIONS

The SGLT2 Inhibitor Dapagliflozin Reduces Liver Fat but Does Not Affect Tissue Insulin Sensitivity: A Randomized, Double-Blind, Placebo Controlled Study With 8-Week Treatment in Type 2 Diabetes Patients

(2019) Aino Latva-Rasku et al.   DIABETES CARE

Glycemic Control, Preexisting Cardiovascular Disease, and Risk of Major Cardiovascular Events in Patients with Type 2 Diabetes Mellitus: Systematic Review With Meta‐Analysis of Cardiovascular Outcome Trials and Intensive Glucose Control Trials

(2019) Dario Giugliano et al.   Journal of the American Heart Association

Prevalence, incidence, and outcome of non-alcoholic fatty liver disease in Asia, 1999–2019: a systematic review and meta-analysis

(2019) Jie Li et al.   Lancet Gastroenterology & Hepatology

Empagliflozin Effectively Lowers Liver Fat Content in Well-Controlled Type 2 Diabetes: A Randomized, Double-Blind, Phase 4, Placebo-Controlled Trial

(2019) Sabine Kahl et al.   DIABETES CARE

Diabetes and Fatty Liver

(2019) Norbert Stefan et al.   EXPERIMENTAL AND CLINICAL ENDOCRINOLOGY & DIABETES

Pioglitazone for the primary and secondary prevention of cardiovascular and renal outcomes in patients with or at high risk of type 2 diabetes mellitus: a meta-analysis

(2019) Yue Zhou et al.   JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM

When and how to use magnetic resonance elastography for patients with liver disease in clinical practice

(2018) Sudhakar Kundapur Venkatesh et al.   AMERICAN JOURNAL OF GASTROENTEROLOGY

Effect of Empagliflozin on Liver Fat in Patients With Type 2 Diabetes and Nonalcoholic Fatty Liver Disease: A Randomized Controlled Trial (E-LIFT Trial)

(2018) Mohammad Shafi Kuchay et al.   DIABETES CARE

Effects of dapagliflozin and n-3 carboxylic acids on non-alcoholic fatty liver disease in people with type 2 diabetes: a double-blind randomised placebo-controlled study

(2018) Jan W. Eriksson et al.   DIABETOLOGIA

Wisteria floribunda agglutinin-positive Mac-2-binding protein and type 4 collagen 7S: useful markers for the diagnosis of significant fibrosis in patients with non-alcoholic fatty liver disease

(2018) Yuji Ogawa et al.   JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY

Effect of luseogliflozin on hepatic fat content in type 2 diabetes patients with non-alcoholic fatty liver disease: A prospective, single-arm trial (LEAD trial)

(2018) Yoshio Sumida et al.   HEPATOLOGY RESEARCH

Non-alcoholic fatty liver disease: causes, diagnosis, cardiometabolic consequences, and treatment strategies

(2018) Norbert Stefan et al.   Lancet Diabetes & Endocrinology

Effect of canagliflozin treatment on hepatic triglyceride content and glucose metabolism in patients with type 2 diabetes

(2018) Kenneth Cusi et al.   DIABETES OBESITY & METABOLISM

Agreement Between Magnetic Resonance Imaging Proton Density Fat Fraction Measurements and Pathologist-Assigned Steatosis Grades of Liver Biopsies From Adults With Nonalcoholic Steatohepatitis

(2017) Michael S. Middleton et al.   GASTROENTEROLOGY

The diagnosis and management of nonalcoholic fatty liver disease: Practice guidance from the American Association for the Study of Liver Diseases

(2017) Naga Chalasani et al.   HEPATOLOGY

Serum Wisteria floribunda agglutinin-positive Mac-2-binding protein levels and liver fibrosis: A meta-analysis

(2017) Kiyoaki Ito et al.   JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY

Long-Term Pioglitazone Treatment for Patients With Nonalcoholic Steatohepatitis and Prediabetes or Type 2 Diabetes Mellitus

(2016) Kenneth Cusi et al.   ANNALS OF INTERNAL MEDICINE

Glucagon and heart in type 2 diabetes: new perspectives

(2016) Antonio Ceriello et al.   Cardiovascular Diabetology

Metabolic Impact of Nonalcoholic Steatohepatitis in Obese Patients With Type 2 Diabetes

(2016) Romina Lomonaco et al.   DIABETES CARE

CV Protection in the EMPA-REG OUTCOME Trial: A “Thrifty Substrate” Hypothesis

(2016) Ele Ferrannini et al.   DIABETES CARE

Magnetic Resonance Imaging More Accurately Classifies Steatosis and Fibrosis in Patients With Nonalcoholic Fatty Liver Disease Than Transient Elastography

(2016) Kento Imajo et al.   GASTROENTEROLOGY

Global epidemiology of nonalcoholic fatty liver disease-Meta-analytic assessment of prevalence, incidence, and outcomes

(2016) Zobair M. Younossi et al.   HEPATOLOGY

EASL–EASD–EASO Clinical Practice Guidelines for the management of non-alcoholic fatty liver disease

(2016)   JOURNAL OF HEPATOLOGY

Thiazolidinediones for nonalcoholic steatohepatitis

(2016) Lingling He et al.   MEDICINE

Effects of sodium-glucose cotransporter-2 inhibitors on cardiovascular events, death, and major safety outcomes in adults with type 2 diabetes: a systematic review and meta-analysis

(2016) Jason H Y Wu et al.   Lancet Diabetes & Endocrinology

Evidence-based clinical practice guidelines for nonalcoholic fatty liver disease/nonalcoholic steatohepatitis

(2015) Sumio Watanabe et al.   JOURNAL OF GASTROENTEROLOGY

Elastography Assessment of Liver Fibrosis: Society of Radiologists in Ultrasound Consensus Conference Statement

(2015) Richard G. Barr et al.   RADIOLOGY

Non-alcoholic fatty liver disease as a cause and a consequence of metabolic syndrome

(2014) Hannele Yki-Järvinen   Lancet Diabetes & Endocrinology

Nonalcoholic Fatty Liver Disease: MR Imaging of Liver Proton Density Fat Fraction to Assess Hepatic Steatosis

(2013) An Tang et al.   RADIOLOGY

Effect of dapagliflozin in patients with type 2 diabetes who have inadequate glycaemic control with metformin: a randomised, double-blind, placebo-controlled trial

(2010) Clifford J Bailey et al.   LANCET

Renal glucose transporters: novel targets for hyperglycemia management

(2010) Amanda Mather et al.   Nature Reviews Nephrology

Pioglitazone, Vitamin E, or Placebo for Nonalcoholic Steatohepatitis

(2010) Arun J. Sanyal et al.   NEW ENGLAND JOURNAL OF MEDICINE

Risk of Cardiovascular Disease in Patients with Nonalcoholic Fatty Liver Disease

(2010) Giovanni Targher et al.   NEW ENGLAND JOURNAL OF MEDICINE

Cytokeratin-18 fragment levels as noninvasive biomarkers for nonalcoholic steatohepatitis: A multicenter validation study

(2009) Ariel E. Feldstein et al.   HEPATOLOGY